Beneath the Surface of Huadong Medicine's Strong Figures: First Non-GAAP Profit Drop, High Receivables, and Cash Flow Strain

Chinese Drug Regulator Accepts Huadong Medicine's Application for Facial Filler's New Indication

Huadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance

Beyond Next Ventures leads SCOHIA PHARMA private funding round raising JPY 3 billion

Huadong Medicine's Subsidiary Gains NMPA Approval for Crohn's Disease Treatments

Huadong Medicine's Unit Gets Nod to Trial HDM2017 for Injection

Huadong Medicine's Attributable Profit Slips 2.8% in 2025

Huadong Medicine Registers New Aesthetics Product Variant in China; Shares Jump 4%

BRIEF-Huadong Medicine 2025 Net Profit Down 2.8% Y/Y

Huadong Medicine's Weight-Loss Drug Marketing Application Accepted in China

CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue

Global First Recombinant Botulinum Toxin Type A Approved, Huadong Medicine Ushers in New Era

China Stocks Jump on Positive Industrial Profit Growth

Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial

Huadong Medicine Subsidiary Gets Nod for HDM2024 Injection Clinical Trial

Huadong Medicine Unit Gets US FDA's Nod to Trial Advanced Tumor Drug

Huadong Medicine's Investigational Drug HDM2024 Receives FDA Clearance for US Clinical Trial

Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications

CARsgen posts FY2025 net loss of CNY103 million, down 87%

Press Release: CARsgen Therapeutics Announces 2025 Annual Results